ESMO 2024: Long-Term Survival Benefit Seen With Nivolumab Plus Ipilimumab in Advanced Melanoma
At minimum of 10 years, nivolumab plus ipilimumab and nivolumab monotherapy demonstrate survival benefit over ipilimumab monotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.